Guardant Health Advances Multi-Product Growth Strategy with Quest Partnership and FDA Milestones
Key Insights
Guardant Health announced a strategic partnership with Quest Diagnostics to integrate Shield (search) colorectal cancer (search) screening into Quest's EMR network, reaching approximately 650,000 physicians and adding co-promotion capabilities.
The company expects FDA approval for Guardant360 (search) in the second half of 2025, which is viewed as a major catalyst with potential ADLT repricing finalization in early 2027 and current ASP of about $3,100.
Shield (search) CRC screening targets a 54 million patient opportunity with 90% of patients not screened in five years, while Reveal MRD (search) represents the company's fastest-growing oncology product.
Guardant Health executives outlined an ambitious multi-product growth strategy during recent investor conferences, highlighting strategic partnerships, regulatory milestones, and commercial expansion plans across their oncology testing portfolio. The company's approach centers on three key products: Shield (search) colorectal cancer (search) screening, Guardant360 (search) therapy selection, and Reveal MRD (search) monitoring.
Quest Partnership Expands Shield Market Access
Co-CEO AmirAli Talasaz announced that Guardant's partnership with Quest Diagnostics aims to make Shield (search) "more broadly available and accessible" through two primary mechanisms: electronic medical record integration and co-promotion. Quest's connectivity system reaches approximately 650,000 physicians, enabling Shield to be incorporated into clinical workflows and ordered more easily.
The partnership will integrate Shield (search) into Quest's EMR network and add co-promotion via Quest's primary care channel. However, Guardant's 2026 guidance does not assume incremental revenue from Quest's co-promotion, with any material impact potentially appearing in the second half of the year.
Shield (search) CRC screening has demonstrated strong launch performance, targeting unscreened patients in what management describes as a 54 million patient opportunity, with approximately 90% of these patients not having been screened in five years. The company's guidance assumes roughly 150% volume growth driven by expanded salesforce productivity, a direct-to-consumer push, and the new Quest partnership to accelerate EMR connectivity.
Guardant360 FDA Approval Expected as Major Catalyst
Management expects Guardant360 (search) FDA approval in the second half of 2025, which is viewed as a major catalyst for the therapy selection franchise. The company anticipates ADLT repricing could be finalized in early 2027, with current average selling price of approximately $3,100. ASP and ADLT improvements are expected to boost gross profit and help achieve cash flow breakeven by the end of 2027.
Guardant360 (search) represents a core hypergrowth driver, with management highlighting ESR1 (search) monitoring in breast cancer (search) tied to AstraZeneca's SERENA-6 trial and an expected FDA decision in the first half of 2025. A recent FDA approval in colorectal cancer (search) could boost physician adoption and payer discussions over time.
Revenue growth drivers for Guardant360 (search) include expanding clinical applications and repeat testing, which currently averages approximately 1.2 to 1.3 tests per patient. The company sees potential momentum from the SERENA-6 context and longitudinal blood-based testing applications.
Reveal MRD Shows Fastest Growth in Oncology Portfolio
Reveal MRD (search) has emerged as Guardant's fastest-growing oncology product, with management expressing strong optimism for 2026 performance. The company plans to launch next-generation Reveal Ultra (search) later this year, though this product is excluded from 2026 revenue guidance due to uncertain reimbursement and adoption timelines.
Commercial Expansion and Financial Outlook
Guardant plans significant commercial expansion with a Shield (search) commercialization push including direct-to-consumer pilots and salesforce growth from 100 to 300 representatives. This expansion will be funded by approximately 14-15% operating expense growth focused on sales and marketing investments.
The company's strategy emphasizes achieving cash flow breakeven by the end of 2027 through multiple revenue growth drivers across its product portfolio, supported by regulatory approvals, reimbursement improvements, and expanded market access through strategic partnerships.